Black Diamond's Silevertinib Shows Steady NSCLC Response, CNS Activity

Black Diamond Therapeutics (NASDAQ: BDTX) provided a May 2026 clinical update on its investigational drug silevertinib for EGFR-mutant non-small cell lung cancer (NSCLC). The data demonstrated steady response rates and CNS activity, along with dose optimization progress. However, durability data remain early.

The Product

Silevertinib is a next-generation, selective EGFR inhibitor designed to target resistance mutations including C797S, with the ability to cross the blood-brain barrier for treating brain metastases. It features broad coverage of EGFR mutations while maintaining high selectivity.

Pricing and Availability

Silevertinib is still in clinical development; pricing and commercial availability have not been announced. Clinical trials are expected to continue for several years before any regulatory submission.

Competition

Silevertinib faces competition from osimertinib (Tagrisso) by AstraZeneca, the current standard of care for first-line EGFR NSCLC. Other competitors include lazertinib and amivantamab. Silevertinib's potential differentiation lies in its activity against resistance mutations like C797S and CNS penetration.

Potential Impact on the Company

If silevertinib demonstrates robust efficacy and durability in later trials, it could represent a significant opportunity for Black Diamond, especially in the multi-billion dollar EGFR NSCLC market. However, risks remain high due to early-stage development and strong competition.